Clinical, Medical and Surgical Oncology

Rare cancers occur in fewer than 6 out of every 100,0000 diagnosed cancers, despite which it accounts for 20% of all cancers diagnosed. We have many advances in treating these, where, FDA has approved a targeted-therapy for anaplastic thyroid carcinoma in 50 years, 177Lu-Dotatate, which delivers targeted radiation to tumour cells, etc. It is also estimated that the global oncology drugs market would reach $176,509 million by 2025.

  • Track 1-1 Radiotherapy
  • Track 2-2 Palliative care
  • Track 3-3 Immunotherapy
  • Track 4-4 Neoadjuvant Therapy
  • Track 5-5 Adjuvant Therapy
  • Track 6-6 Hormonal Therapy
  • Track 7-7 Robotic Oncology
  • Track 8-8 Molecular Profiling
  • Track 9-9 Genetic Profiling
  • Track 10-10 Chemotherapy
  • Track 11-11 Targeted Therapy

Related Conference of Oncology & Cancer